Loading…
← CockpitCompetitor Analysis › ARJO-B.ST Arjo AB Class BOpen in the cockpit ↗

Arjo AB Class BARJO-B.STCompetitor analysis, valuation and peers

Sweden · SEK·Health Care›Medical Distributors
Momentum leader 98
Mkt cap
$974M
US dollars, full cap
Free float
74%
of shares outstanding
$/day
$2.09M
20-day average traded
Fwd P/E
21.1×
forward earnings
ROIC−WACC
+0.4 pp
WACC 5.3%
Hurdle
-5 pp
Req g minus delivered
Next earnings
71 days
28 Jan 2027
Close · SEKSEK 36.38
1D-0.1%
1W+0.3%
1M+29.7%
3M+27.8%
6M+42.3%
YTD+13.6%
1Y+18.2%
ATR %2.2%
52w lowhigh2.4% off high

What Arjo does

Employees: 7,000

Arjo at a glance

Size Arjo (ARJO-B.ST) is a Sweden Health Care company (Medical Distributors) with a market value of $974M, the 131st largest of 220 Sweden companies the cockpit tracks. Shares closed at SEK 36.38 on 18 Nov 2026.

Performance Over six months the shares gained 42.3%, against -3.7% for the median peer and +2.8% for the Sweden market (cap-weighted) — 5th highest of 21 in its peer set.

Growth Revenue fell 0.5% over the last twelve months (peer median +5.3%); the operating margin is 8.0% (peer median 1.9%).

Valuation It trades at 21.1× forward earnings against a peer median of 14.6× (3rd most expensive of 10).

Price implies For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -5 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 0.4 points above its cost of capital (5.3% WACC).

Next results Next results expected around 28 Jan 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026ARJO-B.ST 145Peer median 96
Six months, rebased to 100: Arjo against the median of its 20 peers (local-currency closes).

Arjo financials

Reported figures in SEK; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueSEK 11.1BSEK 11.0BSEK 11.3BSEK 11.0BSEK 9.98B
Revenue growth—-3%+3%+10%—
Gross profitSEK 4.35BSEK 4.36BSEK 4.55BSEK 4.33BSEK 3.80B
EBITDASEK 2.02BSEK 2.01BSEK 2.09BSEK 2.02BSEK 1.73B
Net incomeSEK 361MSEK 334MSEK 498MSEK 480MSEK 449M
Free cash flowSEK 1.21BSEK 1.02BSEK 1.12BSEK 1.66BSEK 269M
Capital expenditureSEK 658MSEK 708MSEK 677MSEK 679MSEK 812M
Total debtSEK 5.35BSEK 5.35BSEK 5.42BSEK 5.49BSEK 6.31B

Quarterly statements and history in the cockpit →

Arjo competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%0%+20%603368600713ENTERO6826301584DOCM7476600587NEU3360RDC60062830137060513666170000784104ARJO-B.ST6-month return →1-month return →
Up and to the right = strong over both horizons. Arjo is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%+30%20×40×603368ENTERO68267476600587NEU33608129ARJO-B.STRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Arjo is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%+60%0%25%50%603368ENTERO68263015847476600587NEU33608129301370605136000078ARJO-B.STGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Arjo is the large dot.

Arjo competitors and peer comparison

How Arjo compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Arjo against its 20 peers (data as of 18 Nov 2026)
MeasureARJO-B.STPeer medianRank in peer set
1-month return+29.7%-3.1%2nd highest of 21
6-month return+42.3%-3.7%5th highest of 21
Distance from 52-week high-2.4%-21.6%highest of 21
Revenue growth (TTM)-0.5%+5.3%6th lowest of 21
Operating margin8.0%1.9%2nd highest of 21
Forward P/E21.1×14.6×3rd most expensive of 10
Growth the price implies (Req g, 7 yrs)-1.0%-1.2%8th most demanding of 16
Growth delivered (Del g)+3.9%+6.0%6th lowest of 16
Hurdle (Req g minus delivered)-5.0 pp-6.3 pp7th most demanding of 16
ROIC minus cost of capital+0.4 pp-0.2 pp9th highest of 21
EV / EBITDA7.1×n/a—
Net debt / EBITDA2.2×0.2×2nd most indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Arjo ARJO-B.STSweden$974M+42%0%8%21.1×-1.0%+3.9%
Guangxi LiuYao 603368.SSChina$975M+1%+2%5%9.5×-9.7%+6.0%
Nanjing Pharmaceutical 600713.SSChina$999M-2%+3%2%n/an/an/a
Entero Healthcare Solutions ENTERO.NSIndia$925M+60%+35%4%47.7×24.7%+29.9%
Shanghai Haohai Biological Technology 6826.HKHong Kong$897M-24%-5%-2%7.7×17.0%+12.4%
Shanghai C and D INNOSTIC Medical Technology 301584.SZChina$1.06B-33%+8%3%n/a-2.7%+17.9%
DocMorris DOCM.SWSwitzerland$1.08B+169%+11%-8%n/an/an/a
AS ONE 7476.TJapan$1.10B+25%+10%12%18.4×0.0%+6.3%
Shinva Medical Instrument 600587.SSChina$1.10B-10%+6%5%13.4×-6.9%+1.2%
Neuca NEU.WAPoland$795M-9%+8%2%15.3×5.3%+8.1%
Ship Healthcare 3360.TJapan$1.38B+19%+6%3%14.6×-14.5%+7.6%
Redcare Pharmacy RDC.DEGermany$1.50B+53%+19%0%n/an/an/a
Toho 8129.TJapan$1.64B-5%+4%1%22.2×-4.6%+5.1%
Arata 2733.TJapan$576M-3%+3%1%12.0×-6.2%+3.8%
Shanghai New World 600628.SSChina$573M-10%-2%6%n/a-1.6%+1.0%
GKHT Medical Technology 301370.SZChina$525M-24%-11%1%n/a13.1%+7.5%
Shanghai Lily & Beauty Cosmetics 605136.SSChina$449M-28%+5%2%n/a21.1%-18.1%
Thalys Medical Technology 603716.SSChina$446M-33%-43%-18%n/an/an/a
Gongwin Biopharm 6617.TWOTaiwan$412M+87%+12%-530%n/an/an/a
Shenzhen Neptunus Bioengineering 000078.SZChina$411M-48%-22%-1%n/a58.3%-7.8%
Excelsior Medical 4104.TWTaiwan$404M+5%+11%8%n/a-1.2%+5.7%

Questions

Which companies are Arjo's closest peers?
The cockpit's peer set: Guangxi LiuYao (603368.SS), Nanjing Pharmaceutical (600713.SS), Entero Healthcare Solutions (ENTERO.NS), Shanghai Haohai Biological Technology (6826.HK), Shanghai C and D INNOSTIC Medical Technology (301584.SZ), DocMorris (DOCM.SW), AS ONE (7476.T), Shinva Medical Instrument (600587.SS).
Is Arjo expensive compared with its peers?
On forward p/e it trades at 21.1× against a peer median of 14.6×, 3rd most expensive of 10 in its peer set. For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -5 pp: the price already allows for a slowdown.
How has Arjo stock performed?
Over six months to 18 Nov 2026 the shares returned +42.3% against -3.7% for the median peer; over one year +18.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.